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Background: Cyclin-dependent kinases (CDKs) control cell cycle progression, RNA transcription and apoptosis, making them
attractive targets for anticancer drug development. Unfortunately, CDK inhibitors developed to date have demonstrated variable
efficacy.
Methods: We generated drug-resistant cells by continuous low-dose exposure to a model pyrazolo[1,5-a]pyrimidine CDK
inhibitor and investigated potential structural alterations for optimal efficacy.
Results: We identified induction of the ATP-binding cassette (ABC) transporters, ABCB1 and ABCG2, in resistant cells.
Assessment of features involved in the ABC transporter substrate specificity from a compound library revealed high polar surface
area (4100Å2) as a key determinant of transporter interaction. We developed ICEC-0782 that preferentially inhibited CDK2, CDK7
and CDK9 in the nanomolar range. The compound inhibited phosphorylation of CDK substrates and downregulated the short-
lived proteins, Mcl-1 and cyclin D1. ICEC-0782 induced G2/M arrest and apoptosis. The permeability and cytotoxicity of ICEC-0782
were unaffected by ABC transporter expression. Following daily oral dosing, the compound inhibited growth of human colon
HCT-116 and human breast MCF7 tumour xenografts in vivo by 84% and 94%, respectively.
Conclusion:We identified a promising pyrazolo[1,5-a]pyrimidine compound devoid of ABC transporter interaction, highly suitable
for further preclinical and clinical evaluation for the treatment of cancer.
Cyclin-dependent kinases (CDK) are proteins that control
progression through the cell cycle (Sherr, 1996). As core elements
of the cell cycle machinery, cyclin D in complex with CDK4/6 and
cyclin E in complex with CDK2 sequentially phosphorylate the
retinoblastoma (Rb) protein facilitating transition from G1- to
S-phase (Sherr, 1994). Moreover, fundamental to cell growth,
cyclin A-CDK1/2 and cyclin B-CDK1 complexes allow progression
through the S-phase and entry into mitosis (Pines, 1991).
Phosphorylation of CDKs by the CDK-activating kinase complex
comprises three subunits – CDK7, cyclin H and MAT1 – is a key
step in the regulation of their activities (Harper and Elledge, 1998;
Fisher, 2005; Lolli and Johnson, 2005). Deregulation of CDK
expression or function via genetic or epigenetic mechanisms is a
common feature of almost all types of cancer as well as other disease
states (Malumbres and Barbacid, 2001). Besides its role in the
regulation of the cell cycle, CDK7 is also required for transcription
initiation by RNA polymerase II (polII). The CDK7/cyclinH/MAT1
complex and cyclin T–CDK9 promote initiation and elongation of
nascent RNA transcripts by phosphorylating the carboxy-terminal
domain of RNA polII (Prelich, 2002; Palancade and Bensaude, 2003;
Meinhart et al, 2005). Because of their critical roles in the regulation
of the cell cycle and transcriptional activity, as well as their impact
on apoptotic pathways, CDKs comprise a favourable set of targets
for anticancer drug development.
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The first generation of CDK inhibitors have entered late-stage
clinical trials but so far have only shown modest activity due to
unfavourable pharmacology. Although the mechanisms responsi-
ble for such poor pharmacology/potency in the clinic are not
entirely clear, potential reasons may include drug efflux in the case
of flavopiridol or poor metabolic stability in the case of
R-roscovitine (seliciclib; CYC202) (Robey et al, 2001; Nutley
et al, 2005). We have previously designed and optimised a number
of pyrazolo[1,5-a]pyrimidine-based CDK inhibitors (Ali et al,
2009; Heathcote et al, 2010). Among these, BS-194 was found to be
a very potent CDK inhibitor, with nanomolar activities against
CDK1, 2, 7 and 9 (Heathcote et al, 2010; Figure 1A). This
compound was efficacious in vitro against a panel of cancer cell
lines from different origins and demonstrated antitumour activity
in human xenograft models of colon and breast cancer (Heathcote
et al, 2010). In the present study, in cells exposed long term to a
CDK inhibitor, we reveal that drug-induced overexpression of the
ATP-binding cassette (ABC) transporters – ABCB1 (also known as
P-glycoprotein, P-gp) and ABCG2 (breast cancer-resistant protein)
– constitutes a major mechanism of drug efflux in vitro and in vivo.
This could be an important mechanism of resistance in future
clinical trials. We identified unfavourable properties in the
pyrazolo[1,5-a]pyrimidine series and, using that information,
synthesised a novel orally active CDK inhibitor devoid of ABC
transporter interaction that inhibits the growth of solid tumours in
mice.
MATERIALS AND METHODS
Cells. HCT-116, A549 and MCF7 cells were obtained from the
American Type Cell Culture Collection (Rockville, MD, USA) and
authenticated by short tandem-repeat profiling under contract by
DDC Medical (London, UK). A2780- and doxorubicin-resistant
subclones A2780AD were provided by the National Cancer Institute
(Bethesda, MD, USA). 3T3 and 3T3 transfected with cDNA
expressing P-gp (pHamdr1) were kindly provided by Dr E Schuetz
from St Jude’s Children Research Hospital (Memphis, TN, USA),
and MCF7- and mitoxantrone (MX)-resistant subclones MCF7-
MX by Dr E Schneider from the University of Maryland
(Baltimore, MD, USA). All cells were passaged in our laboratory
for fewer than 6 months on receipt.
Establishment of HCT-116 and MCF7 cell lines resistant to
BS-194. Cells were originally grown in media containing BS-194
at 40 nM. When cells achieved 80% confluency, they were split and
grown with raised stepwise concentration of BS-194 up to 200 nM
in HCT-116 cells and up to 1.2 mM in MCF7 cells. HCT-116 cells
acquired resistance within 2 weeks, whereas MCF7 cells developed
substantial resistance after 3 months.
Cytotoxicity assay. Drug concentrations that inhibited 50% of cell
growth (GI50) were determined using a sulphorhodamine B
technique as described elsewhere (Vichai and Kirtikara, 2006).
Determination of biophysical properties. The hydrophobicity of
the molecules, LogP, the polar surface area (PSA, defined as the
sum of surfaces of polar atoms, usually oxygens, nitrogens and
their attached hydrogens) and the pKa were calculated using ACD
labs version 12 software (Advance Chemistry Development Inc.,
Toronto, ON, Canada).
Determination of protein expression by flow cytometry.
Collected HCT-116 cells were stained using the monoclonal
antibody to ABCB1 (UlC2) and to ABCG2 (BXP-21) as previously
described (Heathcote et al, 2010). Staining intensity was assessed
by flow cytometry (FACS canto, Becton Dickinson, Mountain
View, CA, USA) and analysed using the FlowJo software (Treestar
Inc., Ashland, OR, USA). Results were expressed as a geometric mean.
Calcein-AM assay. Calcein-AM uptake and conversion to fluor-
escent calcein was determined using the Invitrogen calcein-AM
assay kit according to the manufacturer’s instructions (Invitrogen,
Paisley, UK). Fluorescence was measured by flow cytometry using
FACS canto and the intensity quantified by FlowJo software.
Immunoblotting. Cells were cultured for 24 h and subsequently
treated with different compounds at the indicated concentrations
for 24 h. Protein samples were subsequently prepared by lysing
cells in RIPA buffer (Invitrogen) supplemented with protease and
phosphatase inhibitor cocktails (Sigma, St Louis, MO, USA).
Tumour samples were prepared as follows: excised and snap-
frozen tumour xenografts were homogenised in RIPA lysis buffer
with the PreCellys 24 homogeniser and CK14 bead-containing
tubes (2 cycles of 25 s at 6500 r.p.m.; Bertin Technologies,
Montigny-le-bretonneux, France) and subjected to standard
western blot procedures.
Immunohistochemistry. Tumours treated with BS-194, ICEC-
0782 or vehicle were excised after 14 days of treatment, fixed in
formalin, embedded in paraffin and cut into 5.0-mm sections.
Immunohistochemical staining was performed as described
previously (Heathcote et al, 2010). Data from 10 randomly
selected fields of view per section were captured using an Olympus
BX51 microscope (Olympus UK Ltd, London, UK). Positive cells
were counted using ImageJ software (NIH, Bethesda, MD, USA)
and expressed as a percentage of total cells counted.
Immunofluorescence. Exponentially growing MCF7 and MCF7-MX
cells were seeded in chamber slides on day 1. The cells were treated on
day 2 with 1mM of BS-194 or ICEC-0782 for 24h and stained by
immunofluorescence as described elsewhere (Kaliszczak et al, 2010).
Permeability assay. Permeability of test compounds was per-
formed using the transwell assay as previously described
(Kaliszczak et al, 2010).
Figure 1. Acquired resistance to BS-194 is associated with the expression of ABC transporters in HCT-116 and MCF7 cell lines. (A) Chemical
structure of BS-194. (B) Growth inhibition of BS-194 in HCT-116 parental cells and in HCT-116 cells grown in the presence of BS-194
(HCT-116-BS-194R) as determined by the sulphorhodamine B assay. (C) Levels of ABCB1 expression as determined by flow cytometry in
HCT-116 and HCT-116-BS-194R cells. Results are expressed as geometric mean of the fluorescence intensity. (D) Functional expression of
ABCB1 in HCT-116 and HCT-116-BS-194-R cells as determined by differential uptake of fluorescent dye calcein and flow cytometry.
(E) Levels of ABCG2 expression as determined by flow cytometry in HCT-116 and HCT-116-BS-194R cells compared with expression in
ABCG2-positive MX-resistant cells (MCF7-MX). (F) Growth inhibitory effect of BS-194 in MCF7 parental cells and in MCF7 cells grown in the
presence of BS-194 (MCF7-BS-194R). (G) ABCG2 and ABCB1 expression in MCF7-BS-194R cells as determined by western blotting. Cells were
grown in stepwise increasing concentration of the drug over several passages (p2 to p15). Phamdr1 cells are positive for ABCB1 and negative for
ABCG2. (H) ABCB1 expression in HCT-116 xenografts excised after 14 days of treatment with BS-194 at 25mgkg1 per day (p.o.) as determined
by immunohistochemistry. Results are expressed as a percentage of positive cells (n¼3 tumours per group). (I) ABCG2 expression in MCF7
xenografts excised after 14 days of treatment with BS-194 at 20 mgkg 1 per day (i.p.) as determined by immunohistochemistry. Results are
expressed as a percentage of positive cells (n¼3 tumours per group). Scale bar, 50mm (*Po0.05, ***Po0.0001).
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In vitro kinase assays. Purified recombinant CDK1/cycB1, CDK2/
cycE, CDK4/cycD1, CDK5/p35NCK, CDK6/CycD1, CDK7/CycH/
MAT1 and CDK9/CycT were purchased from Proqinase GmbH
(Freiburg, Germany). Kinase assays were performed as described
previously (Ali et al, 2009), using substrate peptides purchased
from Proqinase GmbH. Measurement of the amount of ATP
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remaining at the end of the reaction, carried out with a luciferase
assay (PKLight assay; Cambrex, Nottingham, UK), was used to
determine inhibition of kinase activity by compounds.
Microsomal stability. Compounds (5mM, final concentration)
were incubated with a mixture 0.1M Tris buffer (Sigma; prepared
with double-distilled water, pH 7.4), 1mM NADPH (Sigma) and
1mgml 1 human or mouse pooled liver microsomes or S9
fractions (BD Biosciences, Oxford, UK) for 1 h at 37 1C in a total
volume of 250 ml. For each sample, proteins were precipitated with
ice-cold methanol (3 volume), centrifuged, resuspended in
mobile phase and filtered (0.2 mm) before HPLC–UV analysis.
Cell cycle analysis. Cells were treated with ICEC-0782 for 24 h.
Collected cells were fixed with ethanol and stained with propidium
iodide (Sigma) in PBS for 3 h. Cell cycle distributions were
determined using flow cytometry (FACS canto, Becton Dickinson)
and analysed using the FlowJo software.
Caspase 3/7 assay. Caspase 3/7 activity was determined using
Promega’s caspase 3/7 assay according to the manufacturer’s
instructions (Promega, Madison, WI, USA). Briefly, cells were
transferred to white opaque 96-well plates, incubated for 1 h with
Caspase-Glo reagent and the enzymatic activity of caspase 3/7 was
measured using a TopCount NXT microplate luminescence
counter (PerkinElmer, Shelton, CT, USA) and normalised to
protein content.
Tumour xenografts. HCT-116 cells (5 106) were injected
subcutaneously in 100 ml volume into the flank of female nu/nu-
BALB/c athymic nude mice. Tumour measurements were
performed daily and volumes were calculated using the formula
(length (mm)) (width (mm)) (depth (mm)) p/6. Treatment
with different compounds was initiated when tumours reached a
volume of 50–100mm3. Throughout the 14-day treatment period,
animal weights and tumour volumes were determined daily. All
animal experiments were done by licensed investigators in
accordance with the United Kingdom Home Office Guidance on
the Operation of the Animal (Scientific Procedures) Act 1986
(HMSO, London, United Kingdom, 1990) and within guidelines
set out by the United Kingdom National Cancer Research Institute
Committee on Welfare of Animals in Cancer Research (Workman
et al, 2010).
[18F]Fluorothymidine positron emission tomography imaging.
Approximately 100mm3 HCT-116 tumour-bearing mice were
treated with ICEC-0782 at 15mg kg 1 BID or with vehicle. At 48 h
post treatment, the animals were scanned on a dedicated small
animal positron emission tomography (PET) scanner (Siemens
Inveon PET module; Siemens, Erlangen, Germany) following a
bolus intravenous injection of B3.7MBq of [18F]Fluorothymidine
([18F]FLT) as previously described (Leyton et al, 2006; Pisaneschi
et al, 2010; Kaliszczak et al, 2013). The uptake value normalised to
the injected dose at 60min (%IDml 1 at 60min) post injection
extracted from time activity curves was used for comparisons
(Pisaneschi et al, 2010).
Ki-67 immunostaining. Tumours treated with ICEC-0782 or
vehicle were excised after imaging, fixed in formalin, embedded in
paraffin and cut into 5.0-mm sections, and tumour proliferation
was determined as previously described (Leyton et al, 2006). Data
from 10 randomly selected fields of view per section were captured
using an Olympus BX51 microscope at  400 magnification.
Ki-67-positive cells were counted using the ImageJ software and
expressed as a percentage of total cells counted.
Statistical analyses. Two tailed Student’s t-tests were performed
using GraphPad prism software (GraphPad, La Jolla, CA, USA),
and P valueso0.05 using a 95% confidence interval were
considered significant. Data are reported as mean±s.e.m. of at
least three independent experiments unless otherwise stated.
*Po0.05, **Po0.005 and ***Po0.0001 were considered to be
statistically significant; NS, not significant.
Additional methods. Synthesis and characterisation of com-
pounds, HPLC–UV method and pharmacokinetic profiling are
described in Supplementary Materials and Methods.
RESULTS
Tumours treated with continuous low-dose BS-194 develop
resistance mediated by ABC transporters ABCB1 and ABCG2.
To elucidate potential mechanisms of resistance to pyrazolo
[1,5-a]pyrimidine CDK inhibitors, HCT-116 cells were grown
in vitro and incubated with an increasing concentration of a
representative CDK inhibitor, BS-194. After 2 weeks of continuous
treatment, HCT-116 cells became 10-fold more resistant to BS-194
(Figure 1B). We evaluated the levels of the major ABC transporters
involved in the multi-drug resistance (MDR) phenotype and found
that ABCB1 was upregulated by 1.7-fold in HCT-116 cells resistant
to BS-194 (HCT-116-BS-194R; Figure 1C). The functional activity
of the transporter was further characterised using the ABCB1
substrate calcein-AM that is converted to its fluorescent dye calcein
within the cell; HCT-116-BS-194R cells were associated with 1.5-
fold less intracellular calcein than their parental counterparts
(Figure 1D). Levels of ABCG2 were not altered (Figure 1E).
Similarly, we generated MCF7 cells resistant to BS-194 (MCF7-BS-
194R) that were 2.5-fold more resistant to BS-194 than the parental
MCF7 cells when comparing their GI50 (Figure 1F). Lower potency
was also observed at the highest concentration tested (i.e., 2.5 mM);
28% of the MCF7-BS-194R cells survived compared with 10% of
the parental cells. Progressive transformation of MCF7-BS-194R
cells over 3 months was associated with an increase of ABCG2
protein levels, which is relatively low compared with MX-resistant
cells (MCF7-MX) that were generated over 9 months (Nakagawa
et al, 1992; Ross et al, 1999; Figure 1G). No differences in ABCB1
protein levels were observed.
To verify whether our initial findings had relevance in vivo, we
evaluated the protein expression of ABCB1 in HCT-116 and
ABCG2 in MCF7 tumour-bearing mice treated with BS-194 over
14 days. Both transporters were upregulated by threefold in the
treated group (Figure 1H and I).
BS-194 is a substrate of the ABC transporters ABCG2 and
ABCB1. We next investigated whether BS-194 is a substrate of the
ABC transporters and actively effluxed from cells. In MCF7 cells,
treatment with BS-194 at 1mM for 24 h abolished the phosphoryla-
tion of polII at ser5, a marker of CDK7 inhibition (Figure 2A).
In MCF7-MX cells that overexpressed ABCG2, similar treatment
with BS-194 did not reduce polII phosphorylation. When treated
continuously for 72 h, MCF7-MX cells were 15 times more
resistant to their parental counterparts with respect to growth
(Figure 2B). Similarly, pHamdr1 cells, which are 3T3 cells stably
transfected with a mdr1 cDNA (overexpressing ABCB1), were
10-fold more resistant to BS-194 than their paired isogenic 3T3
counterparts (Figure 2C). Cross-resistance to BS-194 mediated by
ABCB1 was also demonstrated in A2780AD ovarian cancer cells
that are resistant to doxorubicin (Supplementary Figure S1).
To evaluate whether ABCG2 and ABCB1 could impair cellular
absorption of BS-194, we used human caco-2 monolayers and
determined the ratio between secretion and absorption. The ratio
for BS-194 was 12 (Figure 2D), demonstrating active efflux (ratio
43) (Szakacs et al, 2006). Pretreatment with an ABCG2 inhibitor,
FTC, and the ABCB1 inhibitor, verapamil, reduced the ratio to 2.5.
As a positive control, vinblastine, an ABCB1 substrate, showed a
permeability ratio of 8 that was reduced to 3 following
pretreatment with verapamil.
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High PSA is a major determinant of the interaction of
pyrazolo[1,5-a]pyrimidine derivatives with ABCG2 and ABCB1.
We examined other members of our pyrazolo[1,5-a]pyrimidine
inhibitor family to assess trends that impact on ABC transporter-
mediated efflux. We previously developed another CDK inhibitor,
BS-181, with preferential low nanomolar affinity for CDK7
(Ali et al, 2009). This compound was, however, associated with
an unfavourable pharmacokinetic profile that precluded oral
administration. BS-181 was equipotent in A2780AD cells, over-
expressing ABCB1, and in their parental counterpart, suggesting
that the compound was not a substrate of the transporter
(Supplementary Figure S1). We screened our library of pyr-
azolo[1,5-a]pyrimidine CDK inhibitors to identify non-substrates
of the ABC transporters with potentially favourable absorption and
clearance properties, and satisfactory metabolic stability, to assure
adequate systemic exposure to elicit a pharmacodynamic response
(Ali et al, 2009). Fifteen compounds with nanomolar CDK activity
were selected for further investigation (Supplementary Figure S2
and Supplementary Table S1).
To test ABCG2 substrate specificity, we evaluated the
differential growth inhibitory effect of the series in MCF7-MX
cells (overexpressing ABCG2) and their parental counterparts. We
found that in addition to BS-194, its diastereoisomer, BS-195 and
ICEC-0187 (Supplementary Figure S2), were associated with GI50
ratios 42 (Figure 3A). From previous structure activity relation-
ship (SAR) studies, substrates of ABC transporters share a
common set of properties such as a high molecular weight (MW
4500), 42 aromatic rings, 48 nitrogen and oxygen (NþO)
atoms, a lipophilicity (LogP) between 1 and 5, a pKa 44 and a
PSA 485Å2 (Didziapetris et al, 2003; Varma et al, 2005;
Kaliszczak et al, 2010). Amongst our pyrazolo[1,5-a]pyrimidine
series, we identified a high PSA as a common property shared by
BS-194, BS-194 and ICEC-0187 (Supplementary Table S2).
We hypothesised that the cut-off value should range between
84Å2 (associated with ICEC-0067, a non-substrate) and 104Å2
(associated with ICEC-0187, a substrate).
Similarly, to test ABCB1 substrate specificity we evaluated the
differential growth inhibitory effect in pHamdr1 cells (over-
expressing ABCB1) and their isogenic counterparts, and found that
in addition to BS-194, BS-195 and ICEC-0187 were associated with
ratios 42 (Figure 3B). The impact of another major ABC
transporter, MRP1, on the growth inhibitory effect of the
pyrazolo[1,5-a]pyrimidine derivatives was also evaluated in A549
cells (Pham et al, 2009). No difference in growth inhibition was
seen when the cells were treated with a specific inhibitor of MRP1,
MK-571 (Supplementary Figure S3), indicating that these com-
pounds are not a substrate for MRP1.
Pyrazolo[1,5-a]pyrimidine derivatives with a pKa o7.4 are
associated with favourable permeability. Although BS-181 is not
a substrate for the ABC transporters, it is poorly absorbed; its
chemical structure contains a primary amine that would be
charged at physiological pH, this feature would be predicted to
reduce membrane permeability. To test whether this could be a
feature common to highly basic pyrazolo[1,5-a]pyrimidine deri-
vatives, we evaluated their permeability across the caco-2 cells
(PappA–B). All the compounds with a calculated pKa 47.4
(charged at physiological pH) were poorly absorbed (PappA–B
o3 10 6 cm s 1) (Figure 3C). ICEC-0186 has a calculated pKa
o7.4 but was associated with a poor permeability, indicating either
that pKa alone does not explain permeability or perhaps due to
conversion of ICEC-0186 to a charged entity in the course of the
experiment. Of the remaining compounds with a calculated pKa
o7.4, ICEC-0063 and ICEC-0067 were associated with high
permeability (PappA–B 410 10 6 cm s 1). In contrast, BS-195
and BS-194, with pKa o7.4, were actively effluxed by the ABC
transporters (Figure 3A and B), in turn limiting their absorption
(Figure 3C and D).
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Figure 2. BS-194 is a substrate of the ABC transporters ABCG2 and ABCB1. (A) MCF7 and MCF7-MX cells (overexpressing ABCG2) were
treated with BS-194 at 1 mM for 24 h and stained for phospho-ser5 of polII (red). DAPI staining (DNA) is represented in blue and phalloidin (F-actin)
in green. Scale bar, 20mm. Staining intensities were expressed as percent positive cells per field using 10 random fields of view per chamber
slide (n¼ 3, *** Po0.0001). (B) Growth inhibitory effect of BS-194 in MCF7 cells and MCF7-MX cells. (C) Growth inhibitory effect of BS-194 in
phamdr1 cells overexpressing ABCB1 (3T3 mice fibroblasts transfected with a vector containing human mdr1) and in 3T3 cells (transfected with an
empty vector). (D) Permeability ratios of BS-194 as determined by transwell assay. Results are expressed as ratios of secretion (from the basal
to the apical side; PappB–A) to absorption (from the apical to the basal side; PappA–B). Cells were incubated with BS-194 at 10 mM with or without
addition of inhibitors for ABC transporters (FTC for ABCG2 and verapamil for ABCB1, both at 10mM). Permeability ratios of vinblastine (at 10 mM),
a substrate for ABCB1 but not for ABCG2, are also represented (mean±s.e.m.; n¼3 independent repeats; **P¼0.0012, ***Po0.0001,
NS, not significant).
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Metabolic stability of the pyrazolo[1,5-a]pyrimidine series.
Roscovitine, a CDK inhibitor in clinical trials, undergoes rapid
metabolism in mice and in human, primarily via an NADPH
cytochrome P450 oxidoreductase-dependent process (de la Motte
and Gianella-Borradori, 2004; Nutley et al, 2005). Some of those
metabolites have been synthesised and shown to be much less
potent than the parent compound at inhibiting CDK2 (Nutley et al,
2005). Among the pyrazolo[1,5-a]pyrimidine derivatives, we
identified three classes of compounds: highly metabolised com-
pounds with o10% of parent compound remaining after 60min
incubation of drug with NADPH and mouse S9 fractions (ICEC-
0067, ICEC-0063, ICEC-0179 and ICEC-0186; roscovitine);
compounds with intermediate stability showing 410% but
o50% of parent compound (ICEC-0167 and ICEC-0187); and
stable compounds with 450% of parent compound remaining,
including ICEC-0229 (Supplementary Table S3). Similar classifica-
tion of the series could have been made with mouse microsomes
and human microsomes/S9 fractions, but with different thresholds.
Lead identification, optimisation and characterisation. Among
the pyrazolo[1,5-a]pyrimidine derivatives, ICEC-0229 was identi-
fied as a lead. It was associated with a mean GI50 of 1mM when
tested in HCT-116, MCF7 and A549 cancer cells (Supplementary
Table S4). It was also found not to be a substrate of the ABC
transporters and its metabolic stability was sixfold greater than that
for roscovitine (Figure 3E). However, it possessed unfavourable
permeability properties due to its charge (pKa¼ 10.5) that
prompted the development of analogues of ICEC-0229 that would
be uncharged at physiological pH. Six carbamate derivatives were
synthesised and tested for their growth inhibitory potency in A549
cells (Figure 4A). We found that the length of the aliphatic side
chain was inversely proportional to the biological activity, thus
identifying ICEC-0782 as the most potent carbamate. Using
recombinant enzymes, when compared with ICEC-0229, ICEC-
0782 lost preferential selectivity against CDK7 (16-fold), but gained
3.6-fold higher CDK2 potency and, to a lower extent, CDK9 (1.7-
fold) potency (Figure 4B). Of note, CDK7, CDK2 and CDK9
enzyme inhibition potency remained within the nanomolar range
(170, 71 and 440 nM, respectively). In HCT-116 cells, treatment
with ICEC-0229 or ICEC-0782 for 24 h dose dependently inhibited
phosphorylation of polII at ser2, a marker of CDK9 inhibition
(Figure 4C). Short-lived anti-apoptotic protein Mcl-1 and cell
cycle-regulated protein cyclin D1 were probably inhibited as a
consequence of polII inhibition (Shapiro, 2006).
To test whether the carbamate derivative had an improved
permeability over its parent compound containing a primary amine,
the absorption of ICEC-0782 was tested across caco-2 cells using the
transwell assay. ICEC-0782 was associated with a 10-fold greater
permeability than ICEC-0229 (Figure 4D). ICEC-0782, with a PSA of
95Å2, was associated with a permeability ratio close to 1, suggesting a
lack of active efflux (Figure 4E). This permitted further refinement of
the cut-off value of PSA for the prediction of ABC transporters’
substrate specificity of the pyrazolo[1,5-a]pyrimidines to 100Å2. ICEC-
0782 was found to be potent at inhibiting polII phosphorylation at ser5
(at 1mM for 24h), a marker of CDK7 inhibition, in MCF7-MX cells
(overexpressing ABCG2; Figure 4F), unlike BS-194 (Figure 2A). When
treated at 1mM for 72h, MCF7-MX cells were 1.5-fold more sensitive
to ICEC-0782 than for BS-194 (Figure 4G). The better potency of
ICEC-0782 over BS-194 was also demonstrated in HCT-116-BS-194R
(i.e., 1.3-fold when tested at both 0.5mM and 1mM; Figure 4H).
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The growth inhibitory effect of ICEC-0782 was tested in native
HCT-116 cells and found to be of similar potency as in MCF7 cells
with GI50 of 3.2 and 4.2mM, respectively (Supplementary Table S4).
The cellular effect of ICEC-0782 was further characterised in HCT-
116 cells to investigate the mechanism of growth inhibition. Flow
cytometry studies showed that treatment of cells with ICEC-0782
for 24 h increased the G2/M population at the lowest concentration
tested, i.e., 1mM (from 28% in untreated cells to 34%), probably due
to blockage of CDK7-induced activation of CDK1 (Shapiro, 2006).
Cells also accumulated a sub-G1 fraction in a drug-concentration-
related manner (from 1.5% in untreated cells to 15% at the highest
concentration tested, i.e., 25 mM; Figure 4I), suggesting an apoptotic
mechanism. We confirmed the drug-induced increase in sub-G1 as
occurring via apoptosis by measuring the caspase 3/7 activity:
ICEC-0782 induced a drug-concentration-related increase in
caspase 3/7 activity (Figure 4J). BS-181 also induced caspase 3/7
activation, but only at the highest concentration tested (i.e., 25 mM).
Pharmacokinetic profile of ICEC-0782 favours in vivo anti-
tumour activity. We examined the pharmacokinetic advantage of
ICEC-0782 over ICEC-0229. When given orally at 10mgkg 1, maxi-
mum drug concentration (Cmax) of ICEC-0782 was achieved rapidly
(15min) in contrast to that with ICEC-0229 (120min; Figure 5A and
B). The Cmax and the drug exposure (AUC0–24h) were, respectively, 13-
and 6.5-fold greater than for ICEC-0229. The bioavailability of ICEC-
0782 was also improved by 2.2-fold (from 19% to 42%). The drug was
relatively stable in vivo with a plasma half life of 165min.
Next, we tested whether the potent in vitro activity of ICEC-
0782 combined with its favourable pharmacokinetic features,
favoured efficacy in the human cancer xenograft models. ICEC-
0782 was tested in human colon cancer (HCT-116) xenograft model.
Significant efficacy was obtained when given orally (p.o.) at
15mg kg 1 BID (i.e., 30mg kg 1 per day; Figure 5C). At this dose,
ICEC-0782 treatment was associated with a tumour growth delay
(TGD2x) of 6.6±1.2 days and a tumour growth inhibition (TGI) of
84% compared with vehicle; there was no general toxicity as
determined by changes in body weight (Supplementary Figure S4).
ICEC-0782 was also tested in human breast cancer (MCF7)
xenograft model. The drug was associated with a TGI of 92%
compared with vehicle when given p.o. at 15mg kg 1 BID
(Figure 5D); TGD2x could not be calculated.
In vivo antitumour activity of ICEC-0782 is associated with
molecular and imaging biomarker changes. Biochemical target
modulation in vivo was determined by measuring levels of the
phosphorylated form of Rb protein as a surrogate marker for CDK2
inhibition and phosphorylated forms of polII (at ser2 – a marker for
CDK9 inhibition; and at ser5 – for CDK7). Levels of P-Rb, P-ser2 and
P-ser5 were lower in HCT-116 tumours following 14 days treatment
with ICEC-0782 at 30mgkg 1 per day compared with vehicle
(Figure 6A). Target modulation (e.g., decrease in the levels of P-Rb) was
also seen in the MCF7 xenograft model (Supplementary Figure S5).
In PET studies, radioactivity in tumour regions normalised to
the injected dose was used quantitatively to compare the effects of
ICEC-0782 (Pisaneschi et al, 2010). There was a 1.4-fold decrease
in tumour [18F]FLT uptake in animals treated with ICEC-0782 for
48 h compared with vehicle-treated mice. The tumour uptake was
13.9±0.9 before treatment and decreased to 10±0.8%IDml 1
(P¼ 0.005) at 48h after initiating treatment (Figure 6B). Ki-67
immunostaining decreased in these tumours in keeping with the
reduction in tumour [18F]FLT uptake (1.3-fold; P¼ 0.014; Figure 6C).
It is noteworthy that the MDR phenotype characterised by the
expression of ABC transporters was neither induced in HCT-116
tumours (Figure 6D) nor in MCF7 tumours (Supplementary
Figure S6) after 14 days ICEC-0782.
DISCUSSION
We have developed a novel, orally active pyrazolo[1,5-a]pyrimi-
dine nanomolar CDK inhibitor, ICEC-0782, that inhibits tumour
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growth and is devoid of the induction of MDR phenotype. Cyclin-
dependent kinases are promising targets in cancer therapeutics
because of their key role in cell cycle regulation and transcription
(Sherr, 1996). The less-than impressive outcome of early clinical
trials of CDK inhibitors has been attributed in part to poor
pharmacology (Senderowicz et al, 1998; Nutley et al, 2005; Benson
et al, 2007; Lapenna and Giordano, 2009). In the case of
flavopiridol, reduced activity was due, at least in part, to low
intracellular drug levels consequent to the expression of ABC
transporters (Robey et al, 2001). Of general note, resistance to
chemotherapy, despite initial limited response in some cases, is a
substantial clinical problem accounting for treatment failure in
more than 90% of patients with metastatic disease, the inevitable
outcome being death (Longley and Johnston, 2005). We have
recently reported novel pyrazolo[1,5-a]pyrimidine CDK inhibitors
exemplified by the CDK7 selective inhibitor BS-181 (Ali et al,
2009), as well as BS-194 with preferential activity against CDK1/2/
7/9 (Heathcote et al, 2010). We identified induction of the ABC
transporters, ABCG2 and ABCB1, as a potential mechanism of
de novo and acquired resistance, thus reducing potency. Cells that
expressed these transporters had reduced drug levels. Although it
may be argued that a modest threefold induction of transporter
expression in vivo (Figure 1H and I) could be overcome by dose
escalation, the narrow therapeutic index of most chemotherapeutic
agents may limit this option. A drug devoid of transporter activity
would also be more favourable. Furthermore, analogous to the
induction of acquired resistance, BS-194 induced differential
receptor expression in human colon HCT-116 and human breast
MCF7 cells in culture and in xenografts, with the effects in
tumours occurring with a shorter latency. Although we cannot
explain the mechanism for the differential receptor expression
from a single drug, this phenomenon has been reported with
other chemotherapeutics (Shen et al, 1986; Spoelstra et al, 1991;
Cole et al, 1992; Doyle et al, 1998). Levels of expression of ABCG2
were altered with a different latency after 3 months in vitro and
only after 2 weeks in vivo. Although the specific mechanism
underpinning this difference is unknown, we speculate that tumour
microenvironment factors may have accelerated differential
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receptor expression. Hypoxia and glucose deprivation, hallmarks of
tumour microenvironment, were previously shown to upregulate
ABCG2 via a cis-element close to the reported HIF-1a response
element at the ABCG2 promoter, co-ordinately with pre-existing
MDR mechanism (Cheng and To, 2012). Consistent with
previously published reports, cancer cell lines that were made
resistant to conventional therapeutics such as doxorubicin and MX
were also cross-resistant to BS-194 (Spoelstra et al, 1991; Ross et al,
1999). We showed that drug resistance could be reversed using
pharmacological modulators of ABCG2 and ABCB1, thus
demonstrating biological relevance of the transporters.
One potential mechanism of overcoming MDR phenotype may
be through the inhibition of the ABC transporters; however, as
each compound may have a different specificity towards one or
several transporters, this strategy has significant limitations
(Szakacs et al, 2006; Higgins, 2007; Fletcher et al, 2010). Several
attempts have been made to develop inhibitors of the main ABC
transporters, but these attempts have so far failed to provide
enhanced efficacy in clinical settings (Cripe et al, 2010; Kelly et al,
2011). Another strategy may be through the rational design of
compounds with the same pharmacophore that are not substrates
of the ABC transporters. Using a chemical library approach, we
screened a series of pyrazolo[1,5-a]pyrimidine to identify features
involved in ABC transporter substrate specificity. From previous
SAR studies, compounds with a MW 4500 42 aromatic rings,
48 NþO, LogP between 1 and 5, a pKa44 and PSA485A2 are
likely to be substrates of ABCB1 and ABCG2 (Didziapetris et al,
2003; Varma et al, 2005; Kaliszczak et al, 2010). Analysis of the
physicochemical properties from our series highlighted PSA
(4100Å2) as the main factor controlling the degree of interaction
with ABC transporters, which represents a higher cut-off value that
has been previously described for other series (Varma et al, 2005;
Kaliszczak et al, 2010). Molecular weight was below the optimal
threshold for ABCB1 substrates, and the number of electron donor
groups, as well as aromaticity and lipophicitity, could not
discriminate the substrates from non-substrates. This suggests that
very high PSA would skew the balance of determinants for ABC
transporter substrate specificity. Further analysis of the SAR
revealed that poor cellular permeability occurred with compounds
bearing a charge at physiological pH. Although ICEC-0229
embodied most of the positive attributes discussed above and
was associated with high metabolic stability, it was charged at
physiological pH. Further iteration of the series led to the primary
carbamate, ICEC-0782, that was uncharged at physiological pH.
Unlike ICEC-0229, ICEC-0782 was found to gain potency
towards CDK2 and CDK9, while remaining active against CDK7 in
the nanomolar range. This level of activity was sufficient to inhibit
the phosphorylation of polII and the transcription of short-lived
proteins such as Mcl-1 and cyclin D1 when tested at low
micromolar concentrations. Induction of G2/M and apoptosis by
ICEC-0782 were also in keeping with CDK2/7/9 inhibition.
It appears that functional redundancy among CDKs and cyclin-
binding partners is a frequent event bringing clear implications for
the clinical utility of pan-CDK inhibition (Aleem et al, 2005; Cai
et al, 2006). A growing number of studies have also reported that
concomitant compromise of cell cycle and transcriptional CDK
activities would have more desirable antiproliferative effects in
cancer cells (Cai et al, 2006; Shapiro, 2006). The value of this
strategy is exemplified by the CDK2/7/9 inhibitor SNS-032,
currently in clinical development for treatment of cancer (Tong
et al, 2010). The limited bioavailability of SNS-032, however, was
related to its substrate specificity towards ABCB1 (Kamath et al,
2005). Analogues of SNS-032 with improved permeability have
been synthesised but, to our best of our knowledge, no in vivo
efficacy data are available to date (Choong et al, 2008). Phase III
trials of perhaps the most advanced of the CDK inhibitors,
dinaciclib (a pyrazolo[1,5-a]pyrimidine pan-CDK1/2/5/9 inhibitor
with PSA¼ 91Å2, (NþO)¼ 8, MW¼ 368 and LogP¼ 1.38), has
been initiated in patients with refractory chronic lymphocytic
leukaemia comparing efficacy against ofatumumab (NCT01580228;
http://clinicaltrials.gov/); however, no data on ABC transporter
substrate specificity has been reported (Parry et al, 2010).
We demonstrate that ICEC-0782 is efficacious in vivo. For the
HCT-116 tumour model, this efficacy profile is superior to most
standard of care compounds administered as monotherapy, including
5-fluorouracil, cetuximab and oxaliplatin (Balin-Gauthier et al, 2006;
Wild et al, 2006; Tumber et al, 2007). The molecular and imaging
biomarkers of drug pharmacodynamics – P-Rb, phosphorylated
forms of polII (P-ser2 and P-ser5) and [18F]FLT–PET – validated
in the present study will permit biopsy and non-invasive approach
options to guide go/no-go decision in early clinical trials of
ICEC-0782. Our finding that a modest 1.3-fold decrease in Ki-67
staining at 48 h was sufficient to corroborate [18F]FLT–PET uptake
and predict long-term outcome of ICEC-0782 (i.e., 84% tumour
reduction at 14 days) was in line with previously published data
(Li et al, 2012), wherein a 1.6-fold decrease in Ki-67 after 5 days
of treatment with everolimus was associated with total growth
inhibition at 14 days.
In aggregate, we have identified a novel pyrazolo[1,5-a]
pyrimidine derivative, ICEC-0782 that recapitulated the expected
biochemical behaviour of inhibiting CDK2/7/9, overcame MDR
phenotype mediated by the ABC transporters and further resulted
in antitumour activity. Use of imaging and molecular biochemical
biomarkers of pharmacodynamics identified here will provide a
rationale for the future development of ICEC-0782.
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